TrialBritish journal of clinical pharmacology2022

A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.

Jack A Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.